Abstract: Benz[b]azepine compounds, pharmaceutical compositions containing them and methods for the treatment of neurological disorders utilizing them.

Abstract: Automatic dishwashing detergent compositions, comprising particular quaternary-substituted bleach activators, are provided. More specifically, the invention relates to granular automatic dishwashing detergents which provide enhanced cleaning/bleaching benefits through the selection of quaternary-substituted bleach activators having specific features, such as caprolactam or valerolactam leaving groups and/or the ability to form particular cationic aliphatic peracid structures in solution. Preferred automatic dishwashing compositions comprise amylase enzymes. Included are preferred activator compounds and methods for washing tableware in domestic automatic dishwashing appliances using the activators.

Abstract: A benzolactam derivative represented by the following formula (I): ##STR1## wherein n represents an integer of from 1 to 3; R.sup.1 represents a straight- or branched-chain alkyl group or an aralkyl group; R.sup.2 represents a straight- or branched-chain alkyl group; R.sup.3 and R.sup.4 independently represent a hydrogen atom or a straight- or branched-chain alkyl group, and when R.sup.3 and R.sup.4 are adjacent each other on the phenyl group, they may be combined to form a cycloalkyl ring together with two carbon atoms of the phenyl group to which R.sup.3 and R.sup.4 bind, and said cycloalkyl ring may optionally have one or more substituents; and a anti-retroviral agent comprising the same as an active ingredient.

Abstract: A method of making caprolactam from aminohexanoic acid or aminohexanoate ester comprising the steps of: (a) obtaining a reactor containing at least one catalyst, the catalyst being a metal oxide having acid-base-paired active sites; (b) charging a reaction feed into the reactor, the reaction feed containing a reactant, which is either amniohexanoic acid or C.sub.1 to C.sub.12 alkyl aminohexanoate ester, and a solvent; (c) reacting the reaction feed at a reaction temperature between 140.degree. and 300.degree. C. and a reaction pressure between 10 and 100 atm, to form a product stream; and (d) separating caprolactam from the product stream.

Abstract: Compounds of the formula ##STR1## wherein A is ##STR2## are dual inhibitors of NEP and ACE. Compounds wherein A is ##STR3## are selective ACE inhibitors.

Abstract: Rapamycin derivatives; pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungi growth, inhibit immunosuppression or treat carcinogenic tumors are disclosed.

Abstract: This invention pertains to novel benzodiazepine compounds of formula (I) ##STR1## which exhibit agonistic activity for CCK-A receptors, enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals for use in medicine as anorectic agents in the regulation of appetite, the treatment of obesity and the maintenance of weight loss.

Abstract: Cyclic lactams are prepared by reacting amino carbonitriles with water in liquid phase in a fixed bed reactor in the presence of heterogeneous catalysts which have no soluble constituents under the reaction conditions.

Abstract: A process is provided for preparing cis-(+)-hydroxy-5-[2-(dimethylamine)ethyl]-2,3-dihydro-2-(4-methoxyphenyl) -benzothiazepin-4(5H)-one that is a useful intermediate in the preparation of diltiazem. It has been found that the requisite N-alkylation reaction proceeds rapidly and with an excellent yield when the solvent is a mixture of toluene and N-methylpyrrolidin-2-one and the base is finely-divided sodium carbonate under anhydrous conditions. Such diltiazem commonly is used in the treatment of angina pectoris.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically-acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing the same, which possess immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative activity, as well as the ability to reverse chemotherapeutic drug resistance.

Abstract: Disclosed are the compounds of formula I ##STR1## wherein X represents oxo, one hydroxy or lower alkoxy and one hydrogen, or two hydrogens;R.sub.a and R.sub.b independently represent hydrogen, hydroxy, lower alkoxy, nitro, amino or halogen; or R.sub.a and R.sub.b on adjacent carbons taken together represent lower alkylenedioxy;R.sub.c represents hydrogen, lower alkyl or aryl-lower alkyl;R represents hydrogen or acyl;R.sub.1 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl, biaryl-lower alkyl or trifluoromethyl;R.sub.2 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 together with the carbon to which they are attached represent cycloalkylene or benzo-fused cycloalkylene;m represents one or two;n represents zero or one;COOR.sub.

Abstract: The present invention is concerned with tetrahydronaphthalene derivatives which are mimics of domains of peptides or proteins which can interact with other proteins or with DNA or RNA through .alpha.-helical conformation, said tetrahydronaphthalene derivatives having the formulae: ##STR1## are valuable aids in the determination of biologically active peptide sequences and are accordingly so-called "research tools". They are, however, also potentially suitable as medicaments.

Abstract: The present invention relates to novel substituted hexahydroazepinones and tetrahydrobenzazepinones of the formulae ##STR1## wherein R.sup.1, Z.sup.1, Z.sup.2, W.sup.1, W.sup.2, Y.sup.1 and Y.sup.2 are as defined below, and to novel intermediates used in the synthesis of such compounds.Such compounds are useful in the treatment and prevention of gastrointestinal disorders, pain and anxiety disorders.

Abstract: New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

Abstract: The invention relates to 3-phenylureido-1,5-benzodiazepine-diones of formula (I) ##STR1## and pharmaceutically acceptable salts and solvates thereof, and to their use as gastrin/CCK-B antagonists.

Abstract: This invention relates to compounds of formula (IV) which are useful as intermediates in the preparation of 1,5-benzodiazepine compounds.

Abstract: Novel 9-substituted porphycene compounds are useful in photodynamic therapy.

Abstract: Compounds of the formula ##STR1## are useful as intermediates in the preparation of compounds possessing ACE and NEP inhibition activity.

Abstract: Caprolactam is purified by oxidative treatment in which mixtures which essentially contain the caprolactam to be purified and unsaturated lactams are treated with oxygen or an oxygen-containing gas mixture in an alkaline medium.

Abstract: A compound of the structure ##STR1## wherein R and R.sup.1 are each, independently, hydrogen, or ##STR2## R.sup.2 and R.sup.3 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CN, --NO.sub.2, --SO.sub.2 R.sup.5, --SO.sub.3 R.sup.5, --OR.sup.5, --SR.sup.5, or Ar;R.sup.4 is hydrogen, alkyl, alkenyl, alkynyl, --CF.sub.3, --NR.sup.5 R.sup.6, --CO.sub.2 R.sup.5, --COR.sup.5, CONR.sup.5 R.sup.6, --NO.sub.2, halogen, --OR.sup.5, --SR.sup.5, --CN, --SO.sub.2 R.sup.5, --SO.sub.3 R.sup.5, --SO.sub.2 NR.sup.5 R.sup.6, or Ar;R.sup.5 and R.sup.6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, or Ar;Ar is phenyl, naphthyl, or hetaryl, wherein the foregoing may be optionally substituted;with the proviso that R and R.sup.1 are both not hydrogen, or a pharmaceutically acceptable salt thereof which is useful as an immunosuppressive, antiinflammatory, antifungal, antiproliferative, and antitumor agent.